Related Experiment Videos
Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis
1Department of Radiology, Section of Nuclear Medicine, Hospital of Saint Raphael, New Haven, Connecticut 06511, USA.
Urology
|June 28, 2000
Summary
Indium-111 capromab pendetide (ProstaScint) showed unexpected uptake in neurofibromas, not just prostate cancer. This highlights the importance of considering clinical context to avoid misinterpreting scintigraphy results.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceuticals
Background:
- Prostate-specific antigen (PSA) levels can rise after prostatectomy, necessitating further diagnostic evaluation.
- Indium-111 capromab pendetide (ProstaScint) is an immunoconjugate targeted to prostate carcinoma.
Observation:
- Nonspecific accumulation of indium-111 capromab pendetide was observed in neurofibromas.
- This occurred in a patient with a rising PSA level post-prostatectomy.
Findings:
- The immunoconjugate, designed for prostate cancer, exhibited off-target uptake in a non-malignant entity.
- This demonstrates that nonspecific accumulation can occur in various tissues.
Implications:
- Indium-111 capromab pendetide scintigraphy requires careful interpretation alongside clinical, laboratory, and radiological data.
- Awareness of potential nonspecific uptake is crucial for accurate diagnosis and to prevent misinterpretation of imaging results.